🔎 Trials Near Me

Hjem › Kronisk lymfatisk leukemi › South Carolina

Kliniske studier for Kronisk lymfatisk leukemi i South Carolina

5 studier for Kronisk lymfatisk leukemi søker deltakere på steder i South Carolina.

Byer i South Carolina

Offisiell studietekst (engelsk)

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • AnMed Health Cancer Center, Anderson
  • Prisma Health Richland Hospital, Columbia
  • McLeod Regional Medical Center, Florence
  • og 12 flere
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alder 40 til 75 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT05334069

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

  • Prisma Health Cancer Institute - Spartanburg, Boiling Springs
  • Ralph H Johnson VA Medical Center, Charleston
  • Medical University of South Carolina, Charleston
  • og 6 flere
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 30. sep. 2026 · NCT04269902

A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

  • Medical University of South Carolina, Charleston
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT06973187

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

  • Bon Secours St. Francis Cancer Center, Greenville
RekruttererFase 1/2
Alder 12 og eldre · Alle kjønn · Oppdatert 3. sep. 2026 · NCT04588922

Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL

  • Hollings Cancer Center at Medical University of South Carolina, Charleston
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 27. mar. 2026 · NCT05702853

Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.